FY2025 · ended Dec 31, 2025 · Revenue $46.02M, -89.4% YoY · Filed Feb 25, 2026
Protagonist Therapeutics, Inc (PTGX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $46.0 million and a net loss of $130.1 million. Free cash flow was $56.1 million. As of Jun 30, 2026 it held $849.5 million in cash and investments and $9.2 million in total debt.
Revenue (TTM)
$281.99M
+34.8% vs year-ago TTM
Net income (TTM)
$82.91M
+59.3% vs year-ago TTM
Operating cash flow (TTM)
$131.20M
+231.8% vs year-ago TTM
Free cash flow (TTM)
$130.58M
+252.0% vs year-ago TTM
EPS (TTM)
$1.23
+53.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
63.81M
+3.9% vs prior year
Net cash
$840.24M
as of Jun 30, 2026
Operating margin
20.7%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PTGX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Newark, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1377121
- Former names
- Protagonist Therapeutics Inc (until Jun 11, 2013); Protagonist Inc (until Sep 28, 2006)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $46.0M | $434.4M | $60.0M | $26.6M | $27.4M |
| Operating income | -$158.1M | $252.8M | -$93.7M | -$131.4M | -$125.8M |
| Net income | -$130.1M | $275.2M | -$79.0M | -$127.4M | -$125.6M |
| Diluted EPS | -$2.05 | $4.23 | -$1.39 | -$2.60 | — |
| Operating cash flow | $57.7M | $184.2M | -$70.2M | -$108.1M | -$107.9M |
| Free cash flow | $56.1M | $182.8M | -$70.8M | -$108.9M | -$109.0M |
| Total assets | $668.2M | $744.7M | $358.0M | $247.9M | $347.7M |
| Total liabilities | $53.5M | $69.4M | $21.3M | $32.3M | $47.7M |
| Stockholders' equity | $614.7M | $675.3M | $336.7M | $215.6M | $300.0M |
| Cash and investments | $646.0M | $559.2M | $341.6M | $237.4M | $326.9M |
| Total debt | $10.3M | $10.9M | $1.1M | $3.7M | $5.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 18, 2026 | Jun 17, 2026 |
| 10-Q | Quarterly report | May 5, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 5, 2026 | May 5, 2026 |
All 706 Protagonist Therapeutics, Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.